Sea anemone Kunitz-type peptides demonstrate neuroprotective activity in the 6-hydroxydopamine induced neurotoxicity model
Sintsova, O.; Gladkikh, I.; Monastyrnaya, M.; Tabakmakher, V.; Yurchenko, E.; Menchinskaya, E.; Pislyagin, E.; Andreev, Y.; Kozlov, S.; Peigneur, S.; Tytgat, J.; Aminin, D.; Kozlovskaya, E.; Leychenko, E. (2021). Sea anemone Kunitz-type peptides demonstrate neuroprotective activity in the 6-hydroxydopamine induced neurotoxicity model. Biomedicines 9(3): 283. https://hdl.handle.net/10.3390/biomedicines9030283
In: Biomedicines. MDPI AG: Basel. e-ISSN 2227-9059, meer
|   |
| Trefwoorden |
Radianthus crispa (Hemprich & Ehrenberg in Ehrenberg, 1834) [WoRMS]
Marien/Kust |
| Author keywords |
sea anemones; Kunitz-type proteinase inhibitors; TRPV1; Kv; recombinant peptides; neurotoxicity; 6-OHDA; ROS; DPPH; cytoprotection |
| Auteurs | | Top |
- Sintsova, O.
- Gladkikh, I.
- Monastyrnaya, M.
- Tabakmakher, V.
- Yurchenko, E.
|
- Menchinskaya, E.
- Pislyagin, E.
- Andreev, Y.
- Kozlov, S.
- Peigneur, S., meer
|
- Tytgat, J., meer
- Aminin, D.
- Kozlovskaya, E.
- Leychenko, E.
|
| Abstract |
Kunitz-type peptides from venomous animals have been known to inhibit different proteinases and also to modulate ion channels and receptors, demonstrating analgesic, anti-inflammatory, anti-histamine and many other biological activities. At present, there is evidence of their neuroprotective effects. We have studied eight Kunitz-type peptides of the sea anemone Heteractis crispa to find molecules with cytoprotective activity in the 6-OHDA-induced neurotoxicity model on neuroblastoma Neuro-2a cells. It has been shown that only five peptides significantly increase the viability of neuronal cells treated with 6-OHDA. The TRPV1 channel blocker, HCRG21, has revealed the neuroprotective effect that could be indirect evidence of TRPV1 involvement in the disorders associated with neurodegeneration. The pre-incubation of Neuro-2a cells with HCRG21 followed by 6-OHDA treatment has resulted in a prominent reduction in ROS production compared the untreated cells. It is possible that the observed effect is due to the ability of the peptide act as an efficient free-radical scavenger. One more leader peptide, InhVJ, has shown a neuroprotective activity and has been studied at concentrations of 0.01–10.0 µM. The target of InhVJ is still unknown, but it was the best of all eight homologous peptides in an absolute cell viability increment on 38% of the control in the 6-OHDA-induced neurotoxicity model. The targets of the other three active peptides remain unknown. |
|
